JP2016523963A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523963A5
JP2016523963A5 JP2016525377A JP2016525377A JP2016523963A5 JP 2016523963 A5 JP2016523963 A5 JP 2016523963A5 JP 2016525377 A JP2016525377 A JP 2016525377A JP 2016525377 A JP2016525377 A JP 2016525377A JP 2016523963 A5 JP2016523963 A5 JP 2016523963A5
Authority
JP
Japan
Prior art keywords
phenyl
oxazol
methoxy
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016525377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/045075 external-priority patent/WO2015006100A1/en
Publication of JP2016523963A publication Critical patent/JP2016523963A/ja
Publication of JP2016523963A5 publication Critical patent/JP2016523963A5/ja
Pending legal-status Critical Current

Links

JP2016525377A 2013-07-08 2014-07-01 アリールアミドキナーゼ阻害剤 Pending JP2016523963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843588P 2013-07-08 2013-07-08
US61/843,588 2013-07-08
PCT/US2014/045075 WO2015006100A1 (en) 2013-07-08 2014-07-01 Aryl amide kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018163039A Division JP6573704B2 (ja) 2013-07-08 2018-08-31 アリールアミドキナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2016523963A JP2016523963A (ja) 2016-08-12
JP2016523963A5 true JP2016523963A5 (US08084479-20111227-C00115.png) 2017-07-20

Family

ID=51257588

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016525377A Pending JP2016523963A (ja) 2013-07-08 2014-07-01 アリールアミドキナーゼ阻害剤
JP2018163039A Active JP6573704B2 (ja) 2013-07-08 2018-08-31 アリールアミドキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018163039A Active JP6573704B2 (ja) 2013-07-08 2018-08-31 アリールアミドキナーゼ阻害剤

Country Status (5)

Country Link
US (1) US10253027B2 (US08084479-20111227-C00115.png)
EP (1) EP3019475A1 (US08084479-20111227-C00115.png)
JP (2) JP2016523963A (US08084479-20111227-C00115.png)
CN (1) CN105517993B (US08084479-20111227-C00115.png)
WO (1) WO2015006100A1 (US08084479-20111227-C00115.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383598B2 (ja) 2017-07-21 2023-11-20 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
MX2016012829A (es) 2014-04-02 2017-01-05 Bristol Myers Squibb Co Inhibidores de biaril cinasa.
EP3356330B1 (en) 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
CN112142655A (zh) 2015-10-01 2020-12-29 百时美施贵宝公司 联芳基激酶抑制剂
KR20210108416A (ko) 2018-12-19 2021-09-02 레오 파마 에이/에스 Il-17의 소분자 조절제로서의 아미노산 아닐라이드
CN116209664A (zh) * 2020-06-12 2023-06-02 利奥制药有限公司 Il-17的小分子调节剂
CN112266328B (zh) * 2020-12-09 2023-11-03 郑州萃智医药科技有限公司 3-氟-4-硝基苯甲醛的合成路线及制备方法
CN113321577A (zh) * 2021-06-28 2021-08-31 上海立科化学科技有限公司 5-溴-2-氯苯甲酸的制备方法
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1309036A (en) * 1919-07-08 Trap-stake
US1308935A (en) * 1919-07-08 Hinge for metal boxes or gaits
US4317827A (en) * 1980-05-27 1982-03-02 Sterling Drug Inc. 4-[4(or 3)-Acylaminophenyl]pyridines and their use as cardiotonics
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AU2002352444A1 (en) 2001-12-20 2003-07-09 Celltech R And D Limited Quinazolinedione derivatives
WO2003086325A2 (en) 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2007064054A (ja) 2005-08-30 2007-03-15 Daihatsu Motor Co Ltd 二サイクル式多気筒内燃機関
US8211919B2 (en) * 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
SI2674428T1 (sl) 2006-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Modulatorji transporterjev atp-vezavne kasete
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
WO2009075874A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
US20110038835A1 (en) * 2007-12-21 2011-02-17 The Scripps Research Institute Anilides and analogs as rho kinase inhibitors
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
CA2765012A1 (en) 2009-07-06 2011-01-13 Syngenta Participations Ag Insecticidal compounds
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
EP2552922A1 (en) * 2010-03-31 2013-02-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US20140080834A1 (en) 2012-03-09 2014-03-20 Thomas Herbert Lanthorn Inhibition of adaptor associated kinase 1 for the treatment of pain
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
WO2015026574A1 (en) 2013-08-20 2015-02-26 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
EA029744B1 (ru) 2013-09-11 2018-05-31 Бристол-Майерс Сквибб Компани Ингибиторы киназ на основе простых ариловых эфиров
ES2693771T3 (es) 2014-01-29 2018-12-13 Bristol-Myers Squibb Company Inhibidores de aril lactama quinasa
ES2701903T3 (es) 2014-01-31 2019-02-26 Bristol Myers Squibb Co Inhibidores de cinasa a base de quinolina
MX2016012829A (es) 2014-04-02 2017-01-05 Bristol Myers Squibb Co Inhibidores de biaril cinasa.
EP3177604A1 (en) 2014-08-05 2017-06-14 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
EP3200797A1 (en) 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383598B2 (ja) 2017-07-21 2023-11-20 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤

Similar Documents

Publication Publication Date Title
JP2016523963A5 (US08084479-20111227-C00115.png)
HRP20180916T1 (hr) Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba
JP2008516986A5 (US08084479-20111227-C00115.png)
RU2461551C2 (ru) Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
JP2010533158A5 (US08084479-20111227-C00115.png)
JP2017538750A5 (US08084479-20111227-C00115.png)
NZ724602A (en) Ror-gamma modulators and uses thereof
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JOP20190182B1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
RU2016133626A (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
JP2017506237A5 (US08084479-20111227-C00115.png)
JP2016530310A5 (US08084479-20111227-C00115.png)
RU2017125520A (ru) Соединения, ингибирующие parg
JP2006022108A5 (US08084479-20111227-C00115.png)
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
JP2006077019A5 (US08084479-20111227-C00115.png)
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2013535460A5 (US08084479-20111227-C00115.png)
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
JP2012510989A5 (US08084479-20111227-C00115.png)
JP2012507538A5 (US08084479-20111227-C00115.png)
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
RU2016117941A (ru) Фениколовые противобактериальные средства
JP2014532640A5 (US08084479-20111227-C00115.png)
RU2014121984A (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств